Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus

World Journal of Gastroenterology

Volumn 20, Issue 45, 2014, Pages 17141-17147

  Ye, Jia Zhou ^a   Zhang, Yong Quan ^a   Ye, Hai Hong ^a   Bai, Tao ^a   Ma, Liang ^a   Xiang, Bang De ^a   Li, Le Qun ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Conservative treatment; Hepatocellular carcinoma; Portal vein tumor thrombosis; Postoperative transarterial chemoembolization; Surgical resection; Transarterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DOXORUBICIN; HEPATITIS B SURFACE ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PORTAL VEIN THROMBOSIS; PORTAL VEIN TUMOR THROMBUS; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TRANSARTERIAL CHEMOEMBOLIZATION; TUMOR THROMBUS; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PORTAL VEIN; PROPORTIONAL HAZARDS MODEL; SURGERY; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VENOUS THROMBOSIS;

ADULT; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PORTAL VEIN; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84917706762     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i45.17141     Document Type: Article

References (28)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/ j.gastro.2007.04.061]
2. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH, Lee CM, Wang JH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer 2010; 46: 744-751 [PMID: 20060710 DOI: 10.1016/j.ejca.2009.12.018]
3. Lau WY, Yu SL. Management of portal vein tumor thrombus. In: Lau WY, editor. Hepatocellular carcinoma. Singapore: World scientific publishing. Co Pte Ltd, 2008: 739-760
4. Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Guanghui D, Wenming C, Peijun W, Yuxiang Z. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein. Hepatogastroenterology 2007; 54: 499-502 [PMID: 17523307]
5. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-67 [PMID: 9862851 DOI: 10.1002/hep.510290145]
6. Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, Wu MC, Cheng SQ. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 2010; 17: 2073-2080 [PMID: 20131013 DOI: 10.1245/s10434-010-0940-4]
7. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18: 413-420 [PMID: 20839057 DOI: 10.1245/s10434-010-1321-8]
8. Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001; 233: 379-384 [PMID: 11224626 DOI: 10.1097/00000658-200103 000-00012]
9. Arii S, Tanaka S, Mitsunori Y, Nakamura N, Kudo A, Noguchi N, Irie T. Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography. Oncology 2010; 78 Suppl 1: 125-130 [PMID: 20616594 DOI: 10.1159/000315240]
10. Fan J, Zhou J, Wu ZQ, Qiu SJ, Wang XY, Shi YH, Tang ZY. Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2005; 11: 1215-1219 [PMID: 15754408]
11. Tazawa J, Maeda M, Sakai Y, Yamane M, Ohbayashi H, Kakinuma S, Miyasaka Y, Nagayama K, Enomoto N, Sato C. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001; 16: 660-665 [PMID: 11422619 DOI: 10.1046/ j.1440-1746.2001.02496.x]
12. Ando E, Tanaka M, Yamashita F, Fukumori K, Sumie S, Yano Y, Sata M. Chemotherapy for hepatocellular carcinoma with portal hypertension due to tumor thrombus. J Clin Gastroenterol 2000; 31: 247-249 [PMID: 11034009 DOI: 10.1097/00 004836-200010000-00015]
13. Inoue K, Nakamura T, Kinoshita T, Konishi M, Nakagohri T, Oda T, Takahashi S, Gotohda N, Hayashi T, Nawano S. Volume reduction surgery for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 362-366 [PMID: 15034789 DOI: 10.1007/s00432-004-0566-7]
14. Fukuda S, Okuda K, Imamura M, Imamura I, Eriguchi N, Aoyagi S. Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery 2002; 131: 300-310 [PMID: 11894035 DOI: 10.1067/msy.2002.120668]
15. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234: 63-70 [PMID: 11420484 DOI: 10.1097/000 00658-200107000-00010]
16. Nagasue N, Ono T, Yamanoi A, Kohno H, El-Assal ON, Taniura H, Uchida M. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg 2001; 88: 515-522 [PMID: 11298618 DOI: 10.1046/j.1365-2168.2001.01732.x]
17. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24 [PMID: 10862190 DOI: 10.1097/00000658-200007000-00003]
18. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003; 197: 753-758 [PMID: 14585409 DOI: 10.1016/j.jamcollsurg.2003.07.003]
19. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, Miller CM, Schwartz ME. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533-539 [PMID: 11923610 DOI: 10.1097/00000658-200204000-00012]
20. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: Evaluation pf three kinds of regimens and analysis of prognosis factors. Cancer 2000; 88: 1574-1581 [DOI: 10.1002/(SICI)1097-0142(20000401)88:7 3.0.CO;2-8]
21. Huang YH, Wu JC, Lui WY, Chau GY, Tsay SH, Chiang JH, King KL, Huo TI, Chang FY, Lee SD. Prospective casecontrolled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. World J Surg 2000; 24: 551-555 [PMID: 10787075 DOI: 10.1007/s002689910090]
22. Bruix J, Llovet JM. Two decades of advances in hepatocellular carcinoma research. Semin Liver Dis 2010; 30: 1-2 [PMID: 20175028 DOI: 10.1055/s-0030-1247219]
23. Huang JF, Li SQ, Liang LJ. Efficacy of transarterial chemoembolization for advanced hepatocellular carcinoma. Zhonghua Gandan Waike Zazhi 2010; 1: 3-6
24. Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 2001; 91: 2378-2385 [PMID: 11413528 DOI: 10.1002/1097-0142(20010615)91:12 3.0.CO;2-2]
25. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94: 1747-1752 [PMID: 11920537 DOI: 10.1002/cncr.10407]
26. Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Cong WM, Wang PJ, Zhao YX. [Significance of typing of tumor thrombi in determination of treatment and assessment of prognosis of hepatocellular carcinoma with tumor thrombi in the portal vein] . Zhonghua Yixue Zazhi 2004; 84: 3-5 [PMID: 14990146]
27. Norton L. Adjuvant breast cancer therapy: current status and future strategies-growth kinetics and the improved drug therapy of breast cancer. Semin Oncol 1999; 26: 1-4 [PMID: 10203263]
28. Xia HT, Guo GH, Huang XQ, Wang J. Variations in serum level of cytokines associated with vascular endothelial cells before and after treatment with either TACE and liver resection in patients with hepatocellular carcinoma. Zhonghua Gandan Waike Zazhi 2012; 17: 23-26